Selskabets formål er forskning, udvikling, produktion, markedsføring, salg og/eller licensudstedelse af medicinske produkter til behandling af forskellige sygdomme samt hermed beslægtede aktiviteter efter bestyrelsens skøn.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 71 mio. | -132.1 mio. | 178.2 mio. | -159.6 mio. | 4 | |
CVR: 43259326
Previous names: KemPharm Denmark A/S
Compared to 998 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Timothy Sangiovanni joined the board
Raymond La Duane Clifton left the board
Timothy Sangiovanni joined as ADM. DIR.
Raymond La Duane Clifton left as ADM. DIR.
Rahsaan Waleed Thompson joined the board
Neil McFarlane left the board
Zevra Denmark A/S is currently facing significant financial challenges, as evidenced by its negative profit margins and declining equity. In 2024, the company reported a revenue of 70,973,000 DKK but incurred a substantial loss of 132,114,000 DKK, indicating a troubling trajectory compared to a loss of 20,506,000 DKK in 2023 and 7,406,000 DKK in 2022. The equity position has deteriorated sharply, falling to -159,627,000 DKK in 2024, which raises concerns about its financial stability and ability to attract investment. As a player in the research and experimental development sector, Zevra's current financial state suggests it may struggle to maintain its position without significant operational or strategic changes.
AI-generated summary
Companies in the same industry and area
companydata.dk